|
US6924123B2
(en)
*
|
1996-10-29 |
2005-08-02 |
Oxford Biomedica (Uk) Limited |
Lentiviral LTR-deleted vector
|
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
|
GB0024550D0
(enExample)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
US6933377B2
(en)
*
|
2002-07-29 |
2005-08-23 |
Qun Chen |
Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response
|
|
JP5399612B2
(ja)
*
|
2003-05-16 |
2014-01-29 |
アコーダ セラピューティクス、インク． |
Ｃｎｓを治療するための融合タンパク質
|
|
JP2012511033A
(ja)
*
|
2008-12-08 |
2012-05-17 |
テゴファーム コーポレーション |
多価化合物の可逆阻害用マスキングリガンド
|
|
WO2012135389A2
(en)
*
|
2011-03-28 |
2012-10-04 |
The Regents Of The University Of California |
Host cells and methods for oxidizing aromatic amino acids
|
|
US10400252B2
(en)
*
|
2011-10-28 |
2019-09-03 |
Oxford Biomedica (Uk) Ltd. |
Catecholamine enzyme fusions
|
|
GB201118636D0
(en)
*
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
JP6698114B2
(ja)
*
|
2011-10-28 |
2020-05-27 |
オックスフォード バイオメディカ （ユーケー） リミテッド |
構築物
|
|
HUE063051T2
(hu)
|
2013-02-15 |
2023-12-28 |
Bioverativ Therapeutics Inc |
Optimalizált VIII. faktor gén
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
ES2926585T3
(es)
|
2016-02-01 |
2022-10-27 |
Bioverativ Therapeutics Inc |
Genes de Factor VIII optimizados
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
TWI773695B
(zh)
|
2016-10-12 |
2022-08-11 |
美商生物維瑞提夫美國公司 |
抗Ｃ１ｓ抗體及其使用方法
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
JP7034499B2
(ja)
|
2017-06-27 |
2022-03-14 |
ニューラクル サイエンス カンパニー リミテッド |
線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
|
|
CN110972463B
(zh)
|
2017-06-27 |
2024-05-28 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5抗体在治疗青光眼中的用途
|
|
KR102574549B1
(ko)
|
2017-06-27 |
2023-09-07 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
CN111093700B
(zh)
|
2017-06-27 |
2024-07-16 |
纽洛可科学有限公司 |
抗fam19a5抗体用于治疗癌症的用途
|
|
JP7369121B2
(ja)
|
2017-10-11 |
2023-10-25 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体活性を誘発する方法
|
|
CA3090136A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
|
JP7171081B2
(ja)
|
2018-04-24 |
2022-11-15 |
ニューラクル サイエンス カンパニー リミテッド |
神経病性疼痛の治療のための配列類似性１９、メンバーａ５抗体を有する抗ファミリーの用途
|
|
EP3790898A4
(en)
|
2018-05-10 |
2022-03-02 |
Neuracle Science Co., Ltd |
SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
|
|
US11884729B2
(en)
|
2018-06-29 |
2024-01-30 |
ApitBio, Inc |
Anti-L1CAM antibodies and uses thereof
|
|
KR102648762B1
(ko)
|
2018-10-16 |
2024-03-19 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체의 용도
|
|
WO2020102728A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
TW202039855A
(zh)
|
2018-12-06 |
2020-11-01 |
美商百歐維拉提夫治療公司 |
表現因子ｉｘ之慢病毒載體的用途
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
EP3902826A4
(en)
|
2018-12-27 |
2022-09-14 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT ATHEROSCLEROSIS
|
|
WO2020141452A1
(en)
|
2019-01-02 |
2020-07-09 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
|
EP4090430A1
(en)
|
2020-01-13 |
2022-11-23 |
Neoimmune Tech, Inc. |
Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
|
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
EP4093752A2
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
WO2021158783A1
(en)
|
2020-02-05 |
2021-08-12 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
US20230398216A1
(en)
|
2020-10-22 |
2023-12-14 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
|
KR20230098201A
(ko)
|
2020-10-26 |
2023-07-03 |
네오이뮨텍, 인코퍼레이티드 |
줄기 세포 동원의 유도 방법
|
|
US20240101629A1
(en)
|
2020-11-02 |
2024-03-28 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
CA3195594A1
(en)
|
2020-11-05 |
2022-05-12 |
Byung Ha Lee |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
JP2024520676A
(ja)
|
2021-06-02 |
2024-05-24 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ｎｒ４ａ３欠損免疫細胞及びその使用
|
|
IL311725A
(en)
|
2021-09-30 |
2024-05-01 |
Bioverativ Therapeutics Inc |
Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
|
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
|
KR20240130705A
(ko)
|
2021-12-30 |
2024-08-29 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
|
|
WO2024026490A1
(en)
|
2022-07-28 |
2024-02-01 |
Sqz Biotechnologies Company |
Polynucleotides encoding linked antigens and uses thereof
|
|
EP4615485A1
(en)
|
2022-11-07 |
2025-09-17 |
NeoImmuneTech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|